Aquestive stock: buy or sell?
May 26th, 2020
Should I buy Aquestive stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Aquestive Therapeutics stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Aquestive stock a buy?
Financial institutions and banks post stock ratings everyday.Unfortunately, we couldn't detect any rating for AQST stock for the last 30 days.
Aquestive stock analysis
Shares of Aquestive ended today at $5.16 and plunged a frightening -10.26%.
Aquestive shares plunged -10.26% to $5.16 today. In the last 29 days when AQST stock price broke up the SMA200d line, it gained $1.61 (45.35%). AQST shows a short term strength with several rising tops and rising bottoms. In the very short term, on Thursday it marked a new bottom at $5.58 that should act a support if Aquestive Therapeutics starts a trading flat base in the range of $5.58 - $6.91 Trading the long side, we should wait to a new breakout over $6.91 to find the next buy point.
After climbing for 4 weeks, this week Aquestive collapsed a chilling -10.26%, closing at $5.16. By mid May AQST rocketed an exceptional 6.36% in just one week.
Aquestive Therapeutics is in a glaring downtrend, marking successive declining peaks and bottoms. Now is trading in between the - range. There is an opportunity to rebound and reverse this situation if price can hold above the level. Since early May when AQST stock price broke up the SMA40w line, it gained $0.99 (23.74%).
Aquestive stock price history
Aquestive stock went public on July 25th, 2018 with a price of $15.101. Since then, AQST stock declined a -65.80%, with a yearly average of -65.80%.
1: Adjusted price after possible price splits or reverse-splits.
Aquestive stock historical price chart
AQST stock reached 52-week highs on December at $10.00, and all-time highs 2018-09-13 with a price of 20.7.
Aquestive stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not detected any price forecast for Aquestive stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, Aquestive missed the expectations of the experts and reported a chilling EPS of $-0.56 per share when experts were expecting $-0.91.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw a tiny movement of 0.77% to $67.43 M dollars. In contrary, its profit margin (compared to sales) plunged to -91.02%, that is $-61.38 million.
|2016||$52 M||-||$-9.60 M-18.5%||-|
|2017||$67 M||29.22%||$-8.94 M-13.4%||-6.86%|
|2018||$67 M||0.77%||$-61.38 M-91.0%||586.30%|
Quarterly financial resultsAquestive reported $16.82 million in sales for 2018-Q4, a 26.81% up compared to previous quarter. Reported quarter income marked $-13.94 M with a profit margin of -82.88%. Profit margin skyrocketed a 30.47% compared to previous quarter when profit margin was -113.35%. When comparing turnover to same quarter last year, Aquestive Therapeutics sales marked an amazing increase and boosted a 37.96%.
|2017-Q1||$16 M||-||$-1.46 M-8.9%||-|
|2017-Q2||$11 M||-32.21%||$-5.90 M-52.9%||304.74%|
|2017-Q4||$12 M||9.45%||$-10.04 M-82.3%||70.26%|
|2018-Q1||$23 M||91.97%||$4.10 M17.5%||-140.83%|
|2018-Q2||$14 M||-40.51%||$-36.49 M-262.0%||-990.29%|
|2018-Q3||$13 M||-4.75%||$-15.04 M-113.3%||-58.79%|
|2018-Q4||$17 M||26.81%||$-13.94 M-82.9%||-7.27%|
Aquestive ownershipChecking Aquestive Therapeutics ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Aquestive Therapeutics, 13.68% of all outstanding shares are owned by its staff.
In case of Aquestive stock, 57.50% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AQST stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
|Market cap||$173.3 M|
|Total shares||33.6 M|
|Float shares||27.6 M|
|- Institutional holdings (%)||57.5%|
|- Insider holdings (%)||13.7%|
|Shares in short selling||0.0%|
|Tuesday, May 26th, 2020|
|Day range||$5.02 - $5.81|
|Average true range||$0.73|
|50d mov avg||$3.67|
|100d mov avg||$3.96|
|200d mov avg||$4.29|
Aquestive performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Aquestive to :